drugset / Trial / NCT03657420
Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a combination of drugs as a possible treatment for multiple myeloma. The drugs that will be administered are: * ABI-009 (nab-rapamycin) * Pomalidomide * Dexamethasone
Timeline
- Start
- 2019-05-30
- Primary completion
- 2021-09-30
- Completion
- 2024-09-30
Outcome
Outcome not reported
Stopped (Business): “Funding withdrawn by sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABI-009 | Unknown | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Pomalidomide | Other / unclassified | — | Oral |